Abstract
Baker B, Shen V, Cady R, Ettrup A, and Larsen F. Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies. Cephalalgia Reports. 2022; 5. DOI: 10.1177/25158163221131326
In the above-mentioned article, the data in Table 4 and its associated text have been updated. The revised Table 4 reads as:
Pharmacokinetic parameters of eptinezumab following first dose of administration from Study 1 and Study 2.
Vz and CL are reported for vascular (IV) administration; Vz/F and CL/F are reported for extravascular (SC, IM) administration. AUC: area under the curve; CL: clearance; h: hours; IM: intramuscular; IV: intravenous; NR: not reported; SC: subcutaneous; SD: standard deviation; SMT: sumatriptan; Vz : distribution volume in terminal elimination phase for IV administration for dose 1.
a Results from Study 1.
b Results from Study 2.
c Includes results from Study 1 and Study 2, respectively.
Under Pharmacokinetics, the text “Specifically for the 100-mg and 300-mg IV doses, in Study 1, the plasma half-life for 100 mg IV and 300 mg IV were 22.88 days and 29.5 days, respectively, and 31.5 days for 100 mg IV in Study 2. In addition, the mean C max for 100 mg IV and 300 mg IV were 25.33 µg mL−1 and 93.16 µg mL−1, respectively, and 36.0 for 100 mg IV in Study 2. AUC0–t values for 100 mg IV were 13,655 h·µg mL−1 for Study 1, 15,805,518 h·µg mL−1 for Study 2, and 39,967 h·µg mL−1 for 300 mg in Study 1.”
is revised and should be read as
“Specifically for the 100-mg and 300-mg IV doses, in Study 1, the plasma half-life for 100 mg IV and 300 mg IV were 22.9 days and 29.5 days, respectively, and 31.5 days for 100 mg IV in Study 2. In addition, the mean C max for 100 mg IV and 300 mg IV were 25.33 µg mL−1 and 93.16 µg mL−1, respectively, and 36.0 for 100 mg IV in Study 2. AUC0–t values for 100 mg IV were 13,655 h·µg mL−1 for Study 1, 18,270 h·µg mL−1 for Study 2, and 39,967 h·µg mL−1 for 300 mg in Study 1.”
Under Discussion, the text “Comparatively, in Study 1, the plasma half-life for 100 mg IV and 300 mg IV were 22.88 days and 29.5 days, respectively, and 31.5 days for 100 mg IV in Study 2. The mean Cmax for 100 mg IV and 300 mg IV was 25.33 µg mL−1 and 93.16 µg mL−1, respectively, and 36.0 for 100 mg IV in Study 2. AUC0–t values for 100 mg IV were 13,655 h·µg mL−1 for Study 1 and 2 and 39,967 h·µg mL−1 for 300 mg in Study 1.”
is revised and should be read as
“Comparatively, in Study 1, the plasma half-life for 100 mg IV and 300 mg IV were 22.9 days and 29.5 days, respectively, and 31.5 days for 100 mg IV in Study 2. The mean Cmax for 100 mg IV and 300 mg IV was 25.33 µg mL−1 and 93.16 µg mL−1, respectively, and 36.0 for 100 mg IV in Study 2. AUC0–t values for 100 mg IV were 13,655 h·µg mL−1 for Study 1 and 18,270 h·µg mL–1 for Study 2 and 39,967 h·µg mL−1 for 300 mg in Study 1.”
Additionally, both the Y-axis of Figure 2 were corrected. The updated Figure 2 is:
The correction has been updated in the online version.